{
  "vaccines": [
    {
      "id": "hepb_recombivax",
      "name": "Recombivax HB",
      "type": "HepB",
      "manufacturer": "Merck",
      "description": "Hepatitis B vaccine for infants and children. Given in 3 doses: at birth, 1-2 months, and 6-18 months.",
      "sources": ["hepb_recombivax_insert.pdf"],
      "trial_en": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "The study used another hepatitis B vaccine as the comparator rather than an inert placebo.",
            "level_description": "Mentioned in the document, but inadequately or far below ideal"
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study was conducted in a double-blind manner with neither participants nor investigators knowing allocation.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Subjects were randomly assigned to treatment groups using computer-generated allocation.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "pediatric_sample_size": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "1,636 infants and children were enrolled in the clinical trials.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Subjects were followed for adverse events for 5 days after each dose.",
            "level_description": "Mentioned in the document, but inadequately or far below ideal"
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Data presented for infants and children combined, with limited age-stratified analysis.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Clear inclusion and exclusion criteria were defined, including healthy infants born to HBsAg-negative mothers.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "standardized_adverse_events": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Adverse events were recorded but standardized definitions (e.g., Brighton criteria) were not explicitly used.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Serious adverse events were collected, but monitoring was primarily passive after the initial observation period.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "autoimmune_neurological": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No specific protocol for long-term monitoring of autoimmune or neurological conditions was described.",
            "level_description": "Not conducted or not documented in the document"
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Premature infants and immunocompromised children were excluded from the trials.",
            "level_description": "Mentioned in the document, but inadequately or far below ideal"
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Statistical analysis focused on immunogenicity endpoints; safety analysis was descriptive without power calculations.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Summary data provided in package insert; individual participant data not publicly available.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Post-marketing reports are collected through VAERS and periodic safety updates are conducted.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Study was funded entirely by the manufacturer; no independent analysis mentioned.",
            "level_description": "Mentioned in the document, but inadequately or far below ideal"
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "All-cause mortality data not reported; only vaccine-related deaths discussed.",
            "level_description": "Not conducted or not documented in the document"
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "This vaccine's safety evidence in children is limited by small sample sizes inadequate for detecting rare events, very short follow-up periods, and lack of true placebo control. While basic trial methodology was sound, the study was not designed to detect rare or delayed adverse events."
        }
      },
      "trial_pt": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "O estudo utilizou outra vacina contra hepatite B como comparador em vez de um placebo inerte.",
            "level_description": "Mencionado no documento, mas inadequado ou muito abaixo do ideal"
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O estudo foi conduzido de forma duplo-cega, sem que participantes ou investigadores soubessem a aloca√ß√£o.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os participantes foram randomicamente alocados aos grupos de tratamento usando aloca√ß√£o gerada por computador.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "pediatric_sample_size": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "1.636 beb√™s e crian√ßas foram inclu√≠dos nos ensaios cl√≠nicos.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Os participantes foram acompanhados para eventos adversos por 5 dias ap√≥s cada dose.",
            "level_description": "Mencionado no documento, mas inadequado ou muito abaixo do ideal"
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Dados apresentados para beb√™s e crian√ßas combinados, com an√°lise estratificada por idade limitada.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Crit√©rios de inclus√£o e exclus√£o claros foram definidos, incluindo beb√™s saud√°veis nascidos de m√£es HBsAg-negativas.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "standardized_adverse_events": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Eventos adversos foram registrados, mas defini√ß√µes padronizadas (ex: crit√©rios Brighton) n√£o foram explicitamente usadas.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Eventos adversos graves foram coletados, mas o monitoramento foi principalmente passivo ap√≥s o per√≠odo inicial de observa√ß√£o.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "autoimmune_neurological": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhum protocolo espec√≠fico para monitoramento de longo prazo de condi√ß√µes autoimunes ou neurol√≥gicas foi descrito.",
            "level_description": "N√£o realizado ou n√£o documentado"
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Beb√™s prematuros e crian√ßas imunocomprometidas foram exclu√≠dos dos ensaios.",
            "level_description": "Mencionado no documento, mas inadequado ou muito abaixo do ideal"
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A an√°lise estat√≠stica focou em desfechos de imunogenicidade; a an√°lise de seguran√ßa foi descritiva sem c√°lculos de poder.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Dados resumidos fornecidos na bula; dados individuais dos participantes n√£o dispon√≠veis publicamente.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Relat√≥rios p√≥s-comercializa√ß√£o s√£o coletados atrav√©s do VAERS e atualiza√ß√µes peri√≥dicas de seguran√ßa s√£o conduzidas.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "O estudo foi financiado inteiramente pelo fabricante; nenhuma an√°lise independente mencionada.",
            "level_description": "Mencionado no documento, mas inadequado ou muito abaixo do ideal"
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Dados de mortalidade por todas as causas n√£o relatados; apenas mortes relacionadas √† vacina discutidas.",
            "level_description": "N√£o realizado ou n√£o documentado"
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A evid√™ncia de seguran√ßa desta vacina em crian√ßas √© limitada por amostras pequenas inadequadas para detectar eventos raros, per√≠odos de acompanhamento muito curtos e falta de controle placebo verdadeiro. Embora a metodologia b√°sica do ensaio tenha sido s√≥lida, o estudo n√£o foi desenhado para detectar eventos adversos raros ou tardios."
        }
      },
      "safety_en": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Only 1,636 children studied - insufficient to detect rare events at 1:1,000 rate with statistical confidence."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Follow-up limited to 5 days post-vaccination; completely inadequate for detecting autoimmune or neurological sequelae."
          },
          "comparison_group": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "No true placebo group; another hepatitis B vaccine was used as comparator, obscuring the true adverse event rate."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active surveillance only during initial days; transitioned to passive reporting for serious events."
          },
          "neurological_monitoring": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "No scheduled developmental assessments or long-term neurological follow-up described."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Premature infants and immunocompromised children were excluded; no data on these vulnerable populations."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Summary statistics available in package insert; individual participant data not accessible for independent verification."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "VAERS reporting system mentioned with periodic safety reviews; however, passive reporting underestimates true rates."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The safety evidence for this vaccine in children provides limited reassurance. Short follow-up, small sample size, and lack of true placebo control mean rare and delayed adverse events cannot be ruled out based on this document alone."
        }
      },
      "safety_pt": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Apenas 1.636 crian√ßas estudadas - insuficiente para detectar eventos raros na taxa de 1:1.000 com confian√ßa estat√≠stica."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Acompanhamento limitado a 5 dias p√≥s-vacina√ß√£o; completamente inadequado para detectar sequelas autoimunes ou neurol√≥gicas."
          },
          "comparison_group": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Sem grupo placebo verdadeiro; outra vacina contra hepatite B foi usada como comparador, obscurecendo a taxa real de eventos adversos."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Vigil√¢ncia ativa apenas durante os dias iniciais; transi√ß√£o para notifica√ß√£o passiva para eventos graves."
          },
          "neurological_monitoring": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Nenhuma avalia√ß√£o de desenvolvimento programada ou acompanhamento neurol√≥gico de longo prazo descrito."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Beb√™s prematuros e crian√ßas imunocomprometidas foram exclu√≠dos; sem dados sobre essas popula√ß√µes vulner√°veis."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Estat√≠sticas resumidas dispon√≠veis na bula; dados individuais dos participantes n√£o acess√≠veis para verifica√ß√£o independente."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Sistema de notifica√ß√£o VAERS mencionado com revis√µes peri√≥dicas de seguran√ßa; no entanto, notifica√ß√£o passiva subestima taxas reais."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "A evid√™ncia de seguran√ßa para esta vacina em crian√ßas fornece garantia limitada. Acompanhamento curto, tamanho amostral pequeno e falta de controle placebo verdadeiro significam que eventos adversos raros e tardios n√£o podem ser descartados com base apenas neste documento."
        }
      }
    },
    {
      "id": "hib_hiberix",
      "name": "Hiberix",
      "type": "Hib",
      "manufacturer": "GlaxoSmithKline",
      "description": "Haemophilus influenzae type b vaccine. Given in 4 doses: at 2, 4, 6, and 12-15 months.",
      "sources": ["hib_hiberix_insert.pdf", "hib_hiberix_insert.txt"],
      "trial_en": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No placebo-controlled trials were conducted; all comparisons were against other Hib vaccines.",
            "level_description": "Not conducted or not documented in the document"
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Observer-blinded design used in comparative studies.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Randomized allocation to vaccine groups was performed.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Over 5,000 infants received Hiberix across multiple clinical trials.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Solicited adverse events monitored for 4 days; unsolicited events for 31 days post-vaccination.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Data presented separately for primary series (2-6 months) and booster dose (12-15 months).",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Clear criteria defined; healthy infants meeting age requirements were enrolled.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited local and systemic events were predefined with objective measurement criteria.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Serious adverse events collected throughout the study period; causality assessment performed.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "autoimmune_neurological": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No specific long-term monitoring protocol for autoimmune or neurological conditions described.",
            "level_description": "Not conducted or not documented in the document"
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Premature infants were included in some studies but data not presented separately.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Non-inferiority analysis performed for immunogenicity; safety analysis was descriptive.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Results published in peer-reviewed journals; individual participant data not available.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Post-marketing surveillance data referenced; passive reporting systems in place globally.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "All studies sponsored by GSK; no independent analysis mentioned.",
            "level_description": "Mentioned in the document, but inadequately or far below ideal"
          },
          "all_cause_mortality": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Deaths reported but causality assessment limited to investigator judgment.",
            "level_description": "Present, but with significant flaws or limitations"
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Hiberix has adequate sample sizes and reasonable methodology but lacks placebo control and long-term safety monitoring. The evidence supports short-term safety but cannot address rare or delayed adverse events."
        }
      },
      "trial_pt": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhum ensaio controlado por placebo foi conduzido; todas as compara√ß√µes foram contra outras vacinas Hib.",
            "level_description": "N√£o realizado ou n√£o documentado"
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Desenho com observador cego usado em estudos comparativos.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Aloca√ß√£o randomizada aos grupos de vacina foi realizada.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Mais de 5.000 beb√™s receberam Hiberix em m√∫ltiplos ensaios cl√≠nicos.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Eventos adversos solicitados monitorados por 4 dias; eventos n√£o solicitados por 31 dias p√≥s-vacina√ß√£o.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Dados apresentados separadamente para s√©rie prim√°ria (2-6 meses) e dose de refor√ßo (12-15 meses).",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Crit√©rios claros definidos; beb√™s saud√°veis que atendiam aos requisitos de idade foram inclu√≠dos.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Eventos locais e sist√™micos solicitados foram predefinidos com crit√©rios de medi√ß√£o objetivos.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Eventos adversos graves coletados durante todo o per√≠odo do estudo; avalia√ß√£o de causalidade realizada.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "autoimmune_neurological": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhum protocolo espec√≠fico de monitoramento de longo prazo para condi√ß√µes autoimunes ou neurol√≥gicas descrito.",
            "level_description": "N√£o realizado ou n√£o documentado"
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Beb√™s prematuros foram inclu√≠dos em alguns estudos, mas dados n√£o apresentados separadamente.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "An√°lise de n√£o-inferioridade realizada para imunogenicidade; an√°lise de seguran√ßa foi descritiva.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Resultados publicados em peri√≥dicos revisados por pares; dados individuais dos participantes n√£o dispon√≠veis.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Dados de vigil√¢ncia p√≥s-comercializa√ß√£o referenciados; sistemas de notifica√ß√£o passiva em vigor globalmente.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Todos os estudos patrocinados pela GSK; nenhuma an√°lise independente mencionada.",
            "level_description": "Mencionado no documento, mas inadequado ou muito abaixo do ideal"
          },
          "all_cause_mortality": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Mortes relatadas, mas avalia√ß√£o de causalidade limitada ao julgamento do investigador.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Hiberix tem tamanhos de amostra adequados e metodologia razo√°vel, mas carece de controle placebo e monitoramento de seguran√ßa de longo prazo. A evid√™ncia apoia seguran√ßa de curto prazo, mas n√£o pode abordar eventos adversos raros ou tardios."
        }
      },
      "safety_en": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Over 5,000 infants studied across clinical trials; adequate for detecting events at 1:500 frequency."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Only 31 days of follow-up for unsolicited events; insufficient to detect delayed autoimmune or neurological reactions."
          },
          "comparison_group": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "No placebo control; only compared against other Hib vaccines, making it impossible to determine true background rate of adverse events."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Active solicitation of predefined events for 4 days; passive reporting thereafter."
          },
          "neurological_monitoring": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "No developmental assessments or scheduled neurological evaluations described in the study protocol."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Some premature infants included but results not stratified; immunocompromised children excluded."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Published in peer-reviewed journals but individual participant data not available for independent analysis."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Global pharmacovigilance program in place with periodic safety updates; however reliance on passive reporting."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Hiberix demonstrates reasonable short-term safety in healthy infants with adequate sample sizes. However, the lack of placebo control and limited follow-up duration mean long-term safety and rare events remain uncertain."
        }
      },
      "safety_pt": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Mais de 5.000 beb√™s estudados em ensaios cl√≠nicos; adequado para detectar eventos na frequ√™ncia de 1:500."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Apenas 31 dias de acompanhamento para eventos n√£o solicitados; insuficiente para detectar rea√ß√µes autoimunes ou neurol√≥gicas tardias."
          },
          "comparison_group": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Sem controle placebo; apenas comparado contra outras vacinas Hib, impossibilitando determinar a taxa real de eventos adversos."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Solicita√ß√£o ativa de eventos predefinidos por 4 dias; notifica√ß√£o passiva posteriormente."
          },
          "neurological_monitoring": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Nenhuma avalia√ß√£o de desenvolvimento ou avalia√ß√µes neurol√≥gicas programadas descritas no protocolo do estudo."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Alguns beb√™s prematuros inclu√≠dos, mas resultados n√£o estratificados; crian√ßas imunocomprometidas exclu√≠das."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Publicado em peri√≥dicos revisados por pares, mas dados individuais dos participantes n√£o dispon√≠veis para an√°lise independente."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Programa global de farmacovigil√¢ncia em vigor com atualiza√ß√µes peri√≥dicas de seguran√ßa; no entanto, depend√™ncia de notifica√ß√£o passiva."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Hiberix demonstra seguran√ßa razo√°vel de curto prazo em beb√™s saud√°veis com tamanhos de amostra adequados. No entanto, a falta de controle placebo e dura√ß√£o limitada de acompanhamento significam que a seguran√ßa de longo prazo e eventos raros permanecem incertos."
        }
      }
    },
    {
      "id": "mmr_mmrii",
      "name": "M-M-R II",
      "type": "MMR",
      "manufacturer": "Merck",
      "description": "Measles, Mumps, and Rubella vaccine. Given in 2 doses: at 12-15 months and 4-6 years.",
      "sources": ["mmr_mmrii_clinical.pdf", "mmr_mmrii_clinical.txt"],
      "trial_en": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Original licensure trials included true saline placebo control groups for safety comparison.",
            "level_description": "Exceeds the expected standard for the time period and study type"
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Double-blind methodology employed in pivotal trials.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Randomized allocation performed with documented methods.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Over 14,000 children studied in pre-licensure clinical trials.",
            "level_description": "Exceeds the expected standard for the time period and study type"
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Active follow-up for 42 days; some studies extended to 6 months.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Data presented for 12-15 month age group and school-age children separately.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Well-defined criteria; children with egg allergies and immunodeficiency excluded.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Predefined solicited events with temperature thresholds and rash classifications.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Active surveillance for febrile seizures and other serious events with causality assessment.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Some monitoring for encephalitis and seizures; limited long-term neurological follow-up.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Immunocompromised children excluded from trials; limited data on this population.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Appropriate statistical methods for safety analysis including relative risk calculations.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Extensive publication record; multiple independent studies corroborate findings.",
            "level_description": "Meets what would be expected in a robust safety study"
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Decades of post-marketing surveillance data available; VSD and VAERS data analyzed.",
            "level_description": "Exceeds the expected standard for the time period and study type"
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Initial studies manufacturer-funded; subsequent independent studies conducted.",
            "level_description": "Present, but with significant flaws or limitations"
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "All-cause mortality tracked in clinical trials and post-marketing surveillance.",
            "level_description": "Meets what would be expected in a robust safety study"
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "M-M-R II has one of the most robust safety evidence bases among pediatric vaccines, with large sample sizes, placebo-controlled trials, and decades of post-marketing data. Some limitations remain in long-term autoimmune monitoring and vulnerable subgroup data."
        }
      },
      "trial_pt": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Ensaios originais de licenciamento inclu√≠ram grupos de controle placebo salino verdadeiro para compara√ß√£o de seguran√ßa.",
            "level_description": "Excede o padr√£o esperado para o per√≠odo e tipo de estudo"
          },
          "double_blind": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Metodologia duplo-cega empregada nos ensaios pivotais.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Aloca√ß√£o randomizada realizada com m√©todos documentados.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "Mais de 14.000 crian√ßas estudadas em ensaios cl√≠nicos pr√©-licenciamento.",
            "level_description": "Excede o padr√£o esperado para o per√≠odo e tipo de estudo"
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Acompanhamento ativo por 42 dias; alguns estudos estendidos para 6 meses.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Dados apresentados para grupo et√°rio de 12-15 meses e crian√ßas em idade escolar separadamente.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Crit√©rios bem definidos; crian√ßas com alergia a ovo e imunodefici√™ncia exclu√≠das.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Eventos solicitados predefinidos com limiares de temperatura e classifica√ß√µes de erup√ß√µes cut√¢neas.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "active_monitoring_serious": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Vigil√¢ncia ativa para convuls√µes febris e outros eventos graves com avalia√ß√£o de causalidade.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Algum monitoramento para encefalite e convuls√µes; acompanhamento neurol√≥gico de longo prazo limitado.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Crian√ßas imunocomprometidas exclu√≠das dos ensaios; dados limitados sobre esta popula√ß√£o.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "M√©todos estat√≠sticos apropriados para an√°lise de seguran√ßa incluindo c√°lculos de risco relativo.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Extenso hist√≥rico de publica√ß√µes; m√∫ltiplos estudos independentes corroboram os achados.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "what_document_states": "D√©cadas de dados de vigil√¢ncia p√≥s-comercializa√ß√£o dispon√≠veis; dados do VSD e VAERS analisados.",
            "level_description": "Excede o padr√£o esperado para o per√≠odo e tipo de estudo"
          },
          "conflict_of_interest": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Estudos iniciais financiados pelo fabricante; estudos independentes subsequentes conduzidos.",
            "level_description": "Presente, mas com falhas ou limita√ß√µes significativas"
          },
          "all_cause_mortality": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Mortalidade por todas as causas rastreada em ensaios cl√≠nicos e vigil√¢ncia p√≥s-comercializa√ß√£o.",
            "level_description": "Atende ao esperado em um estudo de seguran√ßa robusto"
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "M-M-R II tem uma das bases de evid√™ncia de seguran√ßa mais robustas entre as vacinas pedi√°tricas, com grandes tamanhos de amostra, ensaios controlados por placebo e d√©cadas de dados p√≥s-comercializa√ß√£o. Algumas limita√ß√µes permanecem no monitoramento autoimune de longo prazo e dados de subgrupos vulner√°veis."
        }
      },
      "safety_en": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Over 14,000 children in clinical trials plus millions in post-marketing surveillance; excellent statistical power."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "42-day active follow-up in trials; however, extensive post-marketing surveillance provides years of data."
          },
          "comparison_group": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Original trials used true saline placebo; rare among pediatric vaccines."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Active solicitation of adverse events with specific attention to febrile seizures and rash."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Monitoring for encephalitis and seizures present; long-term developmental assessments limited."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Immunocompromised children excluded from trials; contraindicated in this population."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Decades of published research from multiple independent research groups; extensive peer review."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "One of the most extensively monitored vaccines; VSD analyses, VAERS, and international databases provide robust safety data."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "M-M-R II has strong safety evidence from well-designed clinical trials and decades of real-world use. The availability of placebo-controlled data and extensive post-marketing surveillance provides considerable confidence in its pediatric safety profile."
        }
      },
      "safety_pt": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Mais de 14.000 crian√ßas em ensaios cl√≠nicos mais milh√µes em vigil√¢ncia p√≥s-comercializa√ß√£o; excelente poder estat√≠stico."
          },
          "follow_up_duration": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "42 dias de acompanhamento ativo nos ensaios; no entanto, extensa vigil√¢ncia p√≥s-comercializa√ß√£o fornece anos de dados."
          },
          "comparison_group": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Ensaios originais usaram placebo salino verdadeiro; raro entre vacinas pedi√°tricas."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Solicita√ß√£o ativa de eventos adversos com aten√ß√£o espec√≠fica a convuls√µes febris e erup√ß√µes cut√¢neas."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Monitoramento para encefalite e convuls√µes presente; avalia√ß√µes de desenvolvimento de longo prazo limitadas."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Crian√ßas imunocomprometidas exclu√≠das dos ensaios; contraindicada nesta popula√ß√£o."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "D√©cadas de pesquisa publicada por m√∫ltiplos grupos de pesquisa independentes; extensa revis√£o por pares."
          },
          "post_marketing_surveillance": {
            "rating": "exemplary",
            "emoji": "‚≠ê",
            "explanation": "Uma das vacinas mais extensamente monitoradas; an√°lises do VSD, VAERS e bases de dados internacionais fornecem dados de seguran√ßa robustos."
          }
        },
        "overall": {
          "rating": "adequate",
          "emoji": "‚úÖ",
          "summary": "M-M-R II tem forte evid√™ncia de seguran√ßa de ensaios cl√≠nicos bem desenhados e d√©cadas de uso no mundo real. A disponibilidade de dados controlados por placebo e extensa vigil√¢ncia p√≥s-comercializa√ß√£o fornece consider√°vel confian√ßa em seu perfil de seguran√ßa pedi√°trica."
        }
      }
    }
  ],
  "criteria_trial": {
    "placebo_control": {
      "id": "placebo_control",
      "name": "Placebo control group",
      "name_pt": "Grupo controle com placebo",
      "why_it_matters": "Allows identification of which reactions are caused by the vaccine vs. coincidental events",
      "why_it_matters_pt": "Permite identificar quais rea√ß√µes s√£o causadas pela vacina vs. eventos coincidentes",
      "what_is_ideal": "Inert placebo (saline). Using another vaccine as comparator obscures true adverse event rates",
      "what_is_ideal_pt": "Placebo inerte (solu√ß√£o salina). Usar outra vacina como comparador obscurece as taxas reais de eventos adversos"
    },
    "double_blind": {
      "id": "double_blind",
      "name": "Double-blind study",
      "name_pt": "Estudo duplo-cego",
      "why_it_matters": "Prevents bias in observation and symptom reporting",
      "why_it_matters_pt": "Previne vi√©s na observa√ß√£o e relato de sintomas",
      "what_is_ideal": "Neither participants nor researchers know who received vaccine/placebo",
      "what_is_ideal_pt": "Nem participantes nem pesquisadores sabem quem recebeu vacina/placebo"
    },
    "randomization": {
      "id": "randomization",
      "name": "Randomization",
      "name_pt": "Randomiza√ß√£o",
      "why_it_matters": "Ensures differences in outcomes are due to the vaccine, not pre-existing characteristics",
      "why_it_matters_pt": "Garante que diferen√ßas nos resultados s√£o devido √† vacina, n√£o caracter√≠sticas pr√©-existentes",
      "what_is_ideal": "Documented random allocation with allocation concealment",
      "what_is_ideal_pt": "Aloca√ß√£o aleat√≥ria documentada com oculta√ß√£o da aloca√ß√£o"
    },
    "pediatric_sample_size": {
      "id": "pediatric_sample_size",
      "name": "Pediatric sample size",
      "name_pt": "Tamanho da amostra pedi√°trica",
      "why_it_matters": "Small samples cannot detect rare reactions. Detecting 1:1,000 events requires ~3,000 participants",
      "why_it_matters_pt": "Amostras pequenas n√£o podem detectar rea√ß√µes raras. Detectar eventos 1:1.000 requer ~3.000 participantes",
      "what_is_ideal": ">3,000 children per age group for adequate safety detection",
      "what_is_ideal_pt": ">3.000 crian√ßas por grupo et√°rio para detec√ß√£o adequada de seguran√ßa"
    },
    "follow_up_duration": {
      "id": "follow_up_duration",
      "name": "Follow-up duration",
      "name_pt": "Dura√ß√£o do acompanhamento",
      "why_it_matters": "Autoimmune/neurological reactions may emerge weeks or months later",
      "why_it_matters_pt": "Rea√ß√µes autoimunes/neurol√≥gicas podem surgir semanas ou meses depois",
      "what_is_ideal": "Minimum 6-12 months; ideal: several years with scheduled assessments",
      "what_is_ideal_pt": "M√≠nimo 6-12 meses; ideal: v√°rios anos com avalia√ß√µes programadas"
    },
    "separate_age_groups": {
      "id": "separate_age_groups",
      "name": "Separate age groups",
      "name_pt": "Grupos et√°rios separados",
      "why_it_matters": "Infants, toddlers, and older children have different immune systems",
      "why_it_matters_pt": "Beb√™s, crian√ßas pequenas e crian√ßas mais velhas t√™m sistemas imunol√≥gicos diferentes",
      "what_is_ideal": "Separate analysis: 0-1 years, 1-5 years, 6-12 years",
      "what_is_ideal_pt": "An√°lise separada: 0-1 ano, 1-5 anos, 6-12 anos"
    },
    "inclusion_exclusion_criteria": {
      "id": "inclusion_exclusion_criteria",
      "name": "Inclusion/exclusion criteria",
      "name_pt": "Crit√©rios de inclus√£o/exclus√£o",
      "why_it_matters": "Allows understanding of who the results apply to",
      "why_it_matters_pt": "Permite entender a quem os resultados se aplicam",
      "what_is_ideal": "Balanced criteria that include representative population",
      "what_is_ideal_pt": "Crit√©rios equilibrados que incluem popula√ß√£o representativa"
    },
    "standardized_adverse_events": {
      "id": "standardized_adverse_events",
      "name": "Standardized definition of adverse events",
      "name_pt": "Defini√ß√£o padronizada de eventos adversos",
      "why_it_matters": "Enables comparison across studies and prevents under/over-reporting",
      "why_it_matters_pt": "Permite compara√ß√£o entre estudos e previne sub/super-notifica√ß√£o",
      "what_is_ideal": "Brighton Collaboration criteria or MedDRA coding",
      "what_is_ideal_pt": "Crit√©rios Brighton Collaboration ou codifica√ß√£o MedDRA"
    },
    "active_monitoring_serious": {
      "id": "active_monitoring_serious",
      "name": "Active monitoring of serious adverse events",
      "name_pt": "Monitoramento ativo de eventos adversos graves",
      "why_it_matters": "Passive/unsolicited reporting vastly underestimates serious events",
      "why_it_matters_pt": "Notifica√ß√£o passiva/n√£o solicitada subestima muito os eventos graves",
      "what_is_ideal": "Active solicited surveillance for hospitalization, sequelae, deaths",
      "what_is_ideal_pt": "Vigil√¢ncia ativa solicitada para hospitaliza√ß√£o, sequelas, mortes"
    },
    "autoimmune_neurological": {
      "id": "autoimmune_neurological",
      "name": "Assessment of autoimmune/neurological reactions",
      "name_pt": "Avalia√ß√£o de rea√ß√µes autoimunes/neurol√≥gicas",
      "why_it_matters": "Conditions like Guillain-Barr√©, seizures, myocarditis are rare but serious",
      "why_it_matters_pt": "Condi√ß√µes como Guillain-Barr√©, convuls√µes, miocardite s√£o raras mas graves",
      "what_is_ideal": "Specific long-term monitoring with scheduled exams",
      "what_is_ideal_pt": "Monitoramento espec√≠fico de longo prazo com exames programados"
    },
    "vulnerable_subgroups": {
      "id": "vulnerable_subgroups",
      "name": "Vulnerable subgroups",
      "name_pt": "Subgrupos vulner√°veis",
      "why_it_matters": "Premature, immunocompromised children may react differently",
      "why_it_matters_pt": "Crian√ßas prematuras, imunocomprometidas podem reagir diferentemente",
      "what_is_ideal": "Intentional inclusion and separate analysis of these groups",
      "what_is_ideal_pt": "Inclus√£o intencional e an√°lise separada desses grupos"
    },
    "statistical_analysis": {
      "id": "statistical_analysis",
      "name": "Robust statistical analysis",
      "name_pt": "An√°lise estat√≠stica robusta",
      "why_it_matters": "Most vaccine trials are powered for efficacy, not safety",
      "why_it_matters_pt": "A maioria dos ensaios de vacinas tem poder para efic√°cia, n√£o seguran√ßa",
      "what_is_ideal": "Study powered for safety outcomes; confidence intervals documented",
      "what_is_ideal_pt": "Estudo com poder para desfechos de seguran√ßa; intervalos de confian√ßa documentados"
    },
    "data_transparency": {
      "id": "data_transparency",
      "name": "Data transparency",
      "name_pt": "Transpar√™ncia dos dados",
      "why_it_matters": "Allows independent verification by other researchers",
      "why_it_matters_pt": "Permite verifica√ß√£o independente por outros pesquisadores",
      "what_is_ideal": "Independent DSMB; raw data available; peer-reviewed publication",
      "what_is_ideal_pt": "DSMB independente; dados brutos dispon√≠veis; publica√ß√£o revisada por pares"
    },
    "post_marketing_surveillance": {
      "id": "post_marketing_surveillance",
      "name": "Post-marketing surveillance",
      "name_pt": "Vigil√¢ncia p√≥s-comercializa√ß√£o",
      "why_it_matters": "Detects rare reactions that only appear in millions of doses",
      "why_it_matters_pt": "Detecta rea√ß√µes raras que s√≥ aparecem em milh√µes de doses",
      "what_is_ideal": "Active pharmacovigilance system with periodic public reports",
      "what_is_ideal_pt": "Sistema ativo de farmacovigil√¢ncia com relat√≥rios p√∫blicos peri√≥dicos"
    },
    "conflict_of_interest": {
      "id": "conflict_of_interest",
      "name": "Conflict of interest / funding source",
      "name_pt": "Conflito de interesse / fonte de financiamento",
      "why_it_matters": "Industry-funded studies are more likely to report favorable outcomes",
      "why_it_matters_pt": "Estudos financiados pela ind√∫stria tendem a relatar resultados favor√°veis",
      "what_is_ideal": "Independent funding or full disclosure of all financial ties",
      "what_is_ideal_pt": "Financiamento independente ou divulga√ß√£o completa de todos os v√≠nculos financeiros"
    },
    "all_cause_mortality": {
      "id": "all_cause_mortality",
      "name": "All-cause mortality and morbidity",
      "name_pt": "Mortalidade e morbidade por todas as causas",
      "why_it_matters": "Focusing only on vaccine-related outcomes can miss overall harm",
      "why_it_matters_pt": "Focar apenas em resultados relacionados √† vacina pode perder danos gerais",
      "what_is_ideal": "Report total deaths and hospitalizations in all groups",
      "what_is_ideal_pt": "Relatar total de mortes e hospitaliza√ß√µes em todos os grupos"
    }
  },
  "criteria_safety": {
    "pediatric_sample_size": {
      "id": "pediatric_sample_size",
      "name": "Pediatric sample size",
      "name_pt": "Tamanho da amostra pedi√°trica",
      "why_it_matters": "Small samples cannot detect rare events (1 in 1,000, 1 in 10,000)",
      "why_it_matters_pt": "Amostras pequenas n√£o podem detectar eventos raros (1 em 1.000, 1 em 10.000)",
      "what_is_ideal": ">3,000 children per age group",
      "what_is_ideal_pt": ">3.000 crian√ßas por grupo et√°rio"
    },
    "follow_up_duration": {
      "id": "follow_up_duration",
      "name": "Follow-up duration",
      "name_pt": "Dura√ß√£o do acompanhamento",
      "why_it_matters": "Autoimmune and neurological problems may take months or years to appear",
      "why_it_matters_pt": "Problemas autoimunes e neurol√≥gicos podem levar meses ou anos para aparecer",
      "what_is_ideal": "Minimum 12 months; 2-3+ years to assess long-term effects",
      "what_is_ideal_pt": "M√≠nimo 12 meses; 2-3+ anos para avaliar efeitos de longo prazo"
    },
    "comparison_group": {
      "id": "comparison_group",
      "name": "Comparison group",
      "name_pt": "Grupo de compara√ß√£o",
      "why_it_matters": "Need a group that did not receive the vaccine for comparison",
      "why_it_matters_pt": "Precisa de um grupo que n√£o recebeu a vacina para compara√ß√£o",
      "what_is_ideal": "True placebo (saline solution), with randomization and double-blind",
      "what_is_ideal_pt": "Placebo verdadeiro (solu√ß√£o salina), com randomiza√ß√£o e duplo-cego"
    },
    "active_surveillance": {
      "id": "active_surveillance",
      "name": "Active surveillance for serious events",
      "name_pt": "Vigil√¢ncia ativa para eventos graves",
      "why_it_matters": "Passive reporting vastly underestimates serious events",
      "why_it_matters_pt": "Notifica√ß√£o passiva subestima muito eventos graves",
      "what_is_ideal": "Regular contact with families, review of medical records, causality analysis",
      "what_is_ideal_pt": "Contato regular com fam√≠lias, revis√£o de prontu√°rios, an√°lise de causalidade"
    },
    "neurological_monitoring": {
      "id": "neurological_monitoring",
      "name": "Neurological/developmental monitoring",
      "name_pt": "Monitoramento neurol√≥gico/desenvolvimento",
      "why_it_matters": "Check if children developed normally months and years later",
      "why_it_matters_pt": "Verificar se as crian√ßas se desenvolveram normalmente meses e anos depois",
      "what_is_ideal": "Scheduled developmental assessments, follow-up neurological exams",
      "what_is_ideal_pt": "Avalia√ß√µes de desenvolvimento programadas, exames neurol√≥gicos de acompanhamento"
    },
    "vulnerable_subgroups": {
      "id": "vulnerable_subgroups",
      "name": "Vulnerable subgroups",
      "name_pt": "Subgrupos vulner√°veis",
      "why_it_matters": "Premature and immunosuppressed children may react differently",
      "why_it_matters_pt": "Crian√ßas prematuras e imunossuprimidas podem reagir diferentemente",
      "what_is_ideal": "These groups intentionally included with results presented separately",
      "what_is_ideal_pt": "Esses grupos intencionalmente inclu√≠dos com resultados apresentados separadamente"
    },
    "data_transparency": {
      "id": "data_transparency",
      "name": "Data transparency",
      "name_pt": "Transpar√™ncia dos dados",
      "why_it_matters": "Is it possible to verify the complete study data?",
      "why_it_matters_pt": "√â poss√≠vel verificar os dados completos do estudo?",
      "what_is_ideal": "Peer-reviewed publication with complete adverse event data",
      "what_is_ideal_pt": "Publica√ß√£o revisada por pares com dados completos de eventos adversos"
    },
    "post_marketing_surveillance": {
      "id": "post_marketing_surveillance",
      "name": "Post-marketing surveillance",
      "name_pt": "Vigil√¢ncia p√≥s-comercializa√ß√£o",
      "why_it_matters": "What was discovered after millions of children received it?",
      "why_it_matters_pt": "O que foi descoberto ap√≥s milh√µes de crian√ßas receberem?",
      "what_is_ideal": "Active pharmacovigilance system with periodic public reports",
      "what_is_ideal_pt": "Sistema ativo de farmacovigil√¢ncia com relat√≥rios p√∫blicos peri√≥dicos"
    }
  },
  "metadata": {
    "generated_at": "2025-01-10T12:00:00Z",
    "vaccines_count": 3,
    "verification_status": "mock_data"
  }
}
